TY - JOUR
T1 - Adjunctive therapies in the treatment of acute coronary syndromes
AU - Miller, Wayne L.
AU - Reeder, Guy S.
N1 - Funding Information:
Digoxin therapy in patients recovering from acute MI remains controversial; clinical trials have generally reported an increased mortali among digoxin-treated patients following acute MI, 75–77 but this may be due to selection bias in observational studies. The Digitalis Investigation Group (DIG), 78 sponsored by the National Institutes of Health, which randomized 6800 patients with CHF, showed no digoxin-related survival benefit and 28% fewer hospitalizations. Recommendations for treatment in patients with acute MI are therefore to avoid digoxin use in the acute setting and to reserve this therapy for the stable post-infarction patient, or to initiate digoxin therapy in the follow-up period if needed.
PY - 2001
Y1 - 2001
N2 - Survival after myocardial infarction has been improving steadily in recent decades, in part because of more effective adjunctive medical therapies. However, the issue of underutilization of effective medical therapies remains. Adjunctive therapy for acute myocardial infarction should include aspirin, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and lipid-lowering agents, all of which improve survival in the treatment and secondary prevention of myocardial infarction. This review presents the current knowledge supporting the use of specific adjunctive pharmacologic agents and also discusses the current status of other agents that are emerging or controversial.
AB - Survival after myocardial infarction has been improving steadily in recent decades, in part because of more effective adjunctive medical therapies. However, the issue of underutilization of effective medical therapies remains. Adjunctive therapy for acute myocardial infarction should include aspirin, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and lipid-lowering agents, all of which improve survival in the treatment and secondary prevention of myocardial infarction. This review presents the current knowledge supporting the use of specific adjunctive pharmacologic agents and also discusses the current status of other agents that are emerging or controversial.
UR - http://www.scopus.com/inward/record.url?scp=0035082271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035082271&partnerID=8YFLogxK
U2 - 10.1016/s0025-6196(11)62387-2
DO - 10.1016/s0025-6196(11)62387-2
M3 - Review article
C2 - 11322355
AN - SCOPUS:0035082271
SN - 0025-6196
VL - 76
SP - 391
EP - 405
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 4
ER -